MoonLake Immunotherapeutics
HealthcareNASDAQ:MLTX · NASDAQ Capital Market
+$0.94 today
Vol 0.74M · Avg 1.00M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$257.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-3.88, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.6M | $0 | $0 | $0 -100.0% | $5.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$2.6M | $0 | $0 | $0 +100.0% | -$5.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $202.9M +79.9% | $112.8M +254.6% | $31.8M -24.4% | $42.0M +18.4% | $35.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $42.0M +38.4% | $30.3M +35.8% | $22.3M -3.0% | $23.0M +27.5% | $18.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $242.2M +69.3% | $143.1M +164.4% | $54.1M -16.8% | $65.1M +21.4% | $53.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.6M +88.9% | $1.4M +273.9% | $370.3K +124.7% | $164.8K +3214.9% | $5.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$219.8M -83.9% | -$119.6M -174.2% | -$43.6M +32.2% | -$64.3M -19.9% | -$53.6M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$244.8M -71.1% | -$143.1M -164.4% | -$54.1M +16.8% | -$65.1M -21.4% | -$53.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $7.2M | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $15.1M -31.7% | $22.1M +118.3% | $10.1M +1613.3% | $591.7K +1056.8% | -$61.8K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$229.7M -89.9% | -$121.0M -175.0% | -$44.0M +31.8% | -$64.5M -20.2% | -$53.6M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $611.0K +116.5% | $282.2K +199.0% | $94.4K +159.6% | $36.4K +664.8% | $4.8K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$227.3M -91.1% | -$118.9M -230.3% | -$36.0M +27.9% | -$50.0M +6.8% | -$53.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 -86.8% | -$2 -158.9% | -$1 +66.8% | -$2 -51.7% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 -86.8% | -$2 -158.9% | -$1 +66.8% | -$2 -51.7% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $64.5M +2.5% | $62.9M +28.0% | $49.1M +67.3% | $29.4M -20.5% | $36.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $64.5M +2.5% | $62.9M +28.0% | $49.1M +67.3% | $29.4M -20.5% | $36.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.37B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
$1.19B
Absci Corporation
NASDAQ:ABSI
$1.06B
Ventyx Biosciences, Inc.
VTYX
$1.00B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$484.08M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Verastem, Inc.
NASDAQ:VSTM
$284.19M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MLTX generate?
MoonLake Immunotherapeutics (MLTX) reported $0.00 of revenue in fiscal 2025.
Is MLTX profitable?
MoonLake Immunotherapeutics (MLTX) reported -$227,318,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.